Total amount raised
$344.3 Millions
Latest funding date
01/01/2025
Location
Absci is leveraging artificial intelligence to create better biologics, advancing a robust pipeline of internal and partnered programs. The company is focused on unlocking novel biology to accelerate the development of biologics for patients.
Keep reading to explore the intricacies of Absci's fundraising journey and the investors backing this innovative platform.
What Is Absci?
Absci is a biotechnology company that leverages AI to unlock novel biology and create better biologics. Their mission is to expedite the drug discovery process, making it faster and more efficient to get life-changing medicines to patients.
Utilizing a combination of wet lab and AI technologies, Absci designs and optimizes biologics through iterative cycles. The company partners with leaders in pharma, tech, and academia to develop differentiated biologics against challenging targets.
How Much Funding Has Absci Raised?
- Venture Round
- Amount Raised: $125M
- Date: March 2021
- Lead Investors: Casdin Capital, Redmile Group
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue innovating and expanding the scope of protein biomanufacturing and to prepare for a potential public offering.
- Corporate Round
- Amount Raised: Not publicly disclosed
- Date: February 2021
- Lead Investors: Merck Global Health Innovation Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the acquisition of Denovium and enhance their synthetic biology platform.
- Series E
- Amount Raised: $70M
- Date: October 2020
- Lead Investors: Casdin Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop their "Protein Printing" technology and expand operations.
- Series D
- Amount Raised: $10.4M
- Date: January 2020
- Lead Investors: JSR Life Sciences, KBI Biopharma
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale up their operations and enhance their biomanufacturing capabilities.
- Debt Financing
- Amount Raised: $5M
- Date: December 2019
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support ongoing research and development activities.
- Series D
- Amount Raised: $10.4M
- Date: January 2019
- Lead Investors: JSR, KBI Biopharma
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand their biomanufacturing platform and increase production capacity.
- Series C
- Amount Raised: $12M
- Date: May 2018
- Lead Investors: AGC
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the development of their protein biomanufacturing technology.
- Series B
- Amount Raised: Not publicly disclosed
- Date: August 2017
- Lead Investors: Phoenix Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop their technology and expand their team.
Total Amount Raised: $258.2M
Current Valuation: Not publicly disclosed
Key Investors
- Casdin Capital
- Details: Casdin Capital is a leading investment firm focused on the life sciences and healthcare sectors. They have a history of backing innovative companies in biotechnology and medical technology.
- Investment Focus Areas: Life sciences, healthcare, biotechnology.
- Notable Investments: Relay Therapeutics, Tango Therapeutics, 10x Genomics.
- Redmile Group
- Details: Redmile Group is an investment firm that specializes in the healthcare sector. They invest in both public and private companies, focusing on transformative healthcare innovations.
- Investment Focus Areas: Healthcare, biotechnology, pharmaceuticals.
- Notable Investments: Moderna, Alnylam Pharmaceuticals, BioNTech.
- Merck Global Health Innovation Fund
- Details: Merck Global Health Innovation Fund is the corporate venture capital arm of Merck & Co. They invest in companies that align with Merck's strategic interests in healthcare innovation.
- Investment Focus Areas: Digital health, diagnostics, healthcare IT.
- Notable Investments: Livongo, Preventice Solutions, WellDoc.
- Fidelity Management
- Details: Fidelity Management is a global investment management firm known for its extensive portfolio across various sectors. They provide capital to both public and private companies.
- Investment Focus Areas: Technology, healthcare, financial services.
- Notable Investments: Tesla, Amazon, Alphabet.
- D1 Capital Partners
- Details: D1 Capital Partners is a global investment firm that invests in both public and private markets. They focus on high-growth sectors and innovative companies.
- Investment Focus Areas: Technology, healthcare, consumer.
- Notable Investments: SpaceX, Stripe, Robinhood.
What's Next for Absci?
Absci's future is brimming with potential as it continues to leverage its "Protein Printing" technology to revolutionize the biomanufacturing industry. With significant financial backing and a focus on reducing failure rates, the company is poised to create new medicines and improve human health. The recent $125 million funding round, described as "crossover financing," hints at a potential IPO, opening doors for further capital influx.
However, the path ahead is not without challenges. The competitive biotech landscape demands continuous innovation, and scaling up production while ensuring the reliability of their technology will be crucial. Navigating regulatory approvals for new biomanufacturing processes adds another layer of complexity. Yet, with strong investor support and a clear vision, Absci is well-positioned to overcome these hurdles and achieve its ambitious goals.
Use Clay to Get Funding Data
Sales professionals, leverage Clay's platform to access comprehensive fundraising data on companies like Absci and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
